"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial ...

Absci Corp. is the drug and target discovery ... The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci management is scheduled to participate in a fireside chat on Wednesday, February 5 th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived ...

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy ...

VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be ...

The investment sent Absci shares up nearly 11% in early trading Wednesday, to $3.41, even though the companies didn’t disclose the price AMD is paying for shares in the Vancouver company.

Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn ( @absci ), X ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI ... potential first-in-class therapeutics VANCOUVER, Wash. and PARIS, Jan. 10, 2025 ...